Sign in

    Chen Chen

    Research Analyst at UBS Group

    Chen Chen is an Analyst at UBS Group, specializing in equity research within the financial sector. While detailed information about the exact companies covered and quantitative performance metrics are not publicly available, Chen is known for providing in-depth analysis for institutional clients as part of the UBS research team. With a solid background in finance and a career focused on equity research, Chen has contributed to UBS since joining the team, leveraging strong analytical skills and industry insight. Professional credentials and specific licenses are not disclosed in public records, and no recent industry rankings or awards have been attributed to this analyst.

    Chen Chen's questions to HUTCHMED (China) (HCM) leadership

    Chen Chen's questions to HUTCHMED (China) (HCM) leadership • H1 2025

    Question

    Chen Chen of UBS Group asked about the potential impact of proposed US tariffs on fruquintinib sales. She also questioned the NDA submission timeline for savolitinib in gastric cancer and the company's plans for NRDL negotiations for its EZH2 inhibitor, Tesveric.

    Answer

    CEO Weiguo Su stated that while the details are unknown, he believes the impact of potential US tariffs on fruquintinib would not be significant due to the relatively low manufacturing cost. He confirmed that the NDA filing for savolitinib in late-stage gastric cancer is planned for the end of the current year. Regarding the EZH2 inhibitor, Dr. Su affirmed that the company is preparing for NRDL discussions later this year, acknowledging the product's higher cost as an imported drug and its initial indication in a rare form of lymphoma.

    Ask Fintool Equity Research AI